Remdesivir News and Research

RSS

Clinical trial to test safety, efficacy of antibody treatment in hospitalized COVID-19 patients

Patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a clinical trial to test the safety and efficacy of a potential new treatment for the disease.

4 Aug 2020

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale School of Medicine and the biopharmaceutical firm AI Therapeutics have launched a multi-institutional clinical trial of a drug for treating COVID-19.

27 Jul 2020

Seaweed extract outperforms remdesivir in inhibiting SARS-CoV-2 in cell studies

In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease.

24 Jul 2020

Compelling study shows heparin may protect against COVID-19

A compelling new study conducted by an international team of researchers has demonstrated that the widely used blood-thinning medication - heparin - can block infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

16 Jul 2020

Researcher and health research journalist point out biased misinformation on coronavirus

In a new JAMA editorial, a Boston University School of Public Health (BUSPH) researcher and a health research journalist outline common ways that media, governments, and industry and academic public relations press releases have incompletely and misleadingly reported coronavirus research, and how they can do better.

14 Jul 2020

People with accelerated biological age at increased risk of COVID-19 symptom severity and mortality

Now, a new study published on the preprint server medRxiv in July 2020 discusses the explanation in terms of the biological aging markers in patients with severe disease, rather than the chronological age.

13 Jul 2020

COVID-19 – researchers sum up the “Tsunami” of information

The severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection leading to COVID-19 is a raging pandemic across the world at present. It has infected 13 million and killed 571,000 individuals around the world as of today. The infection was first reported in Wuhan, Hubei Province of China in late December 2019.

13 Jul 2020

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Researchers from the National Institutes of Health (NIH) and Cornell University in the U.S. just described several new inhibitors of human coronavirus spike proteins by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Their exciting findings are currently available on the bioRxiv preprint server.

13 Jul 2020

Remdesivir potently inhibits SARS-CoV-2 in human lung cell cultures

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better.

9 Jul 2020

SARS-CoV-2 a dagger to the aging heart

Researchers in Europe have shown that genes involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are expressed to a higher degree in older heart muscle cells (cardiomyocytes) than they are in younger cardiomyocytes.

9 Jul 2020

Small molecule drugs binding Mac1 domain of SARS-CoV-2

Now, an intriguing new study out of the University of Wisconsin-Milwaukee reveals that numerous small molecule drugs like the proton pump inhibitors omeprazole and rabeprazole bind the important Mac1 domain on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.

8 Jul 2020

BUSPH study outlines how remdesivir could save lives in countries with less hospital capacity

Amid news that the United States has bought up virtually the entire global supply of remdesivir, a new Boston University School of Public Health (BUSPH) study outlines how the drug could save lives in countries with less hospital capacity, such as South Africa, where COVID-19 is beginning to overwhelm intensive care units (ICUs).

7 Jul 2020

Dutch trial of convalescent plasma in COVID-19 discontinued

Now, a recent trial published on the preprint server medRxiv* in July 2020 reports that a majority of hospitalized COVID-19 patients have a high titer of neutralizing antibodies, at the time of admission, within 10 days of symptomatic disease.

7 Jul 2020

New platform prioritizes synergistic drug combinations against SARS-CoV-2

Researchers in the U.S. have used a new web-based platform to help identify synergistic and antagonistic drug combinations and their underlying mechanisms of action in the context of coronavirus disease 2019 (COVID-19).

2 Jul 2020

New assay rapidly tests SARS-CoV-2 neutralization and screens antivirals

Researchers at the University of Texas Medical Branch, Galveston, have developed a new platform that can rapidly test neutralizing antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and perform high-throughput screening of potential antiviral agents.

24 Jun 2020

Dexamethasone could benefit certain hospitalized COVID-19 patients

The RECOVERY Collaborative Group has released a preliminary report describing the effects of dexamethasone treatment among patients hospitalized with coronavirus disease 2019 (COVID-19).

23 Jun 2020

FDA approved drugs active against COVID-19

With the rapid spread of the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) throughout the world, causing the current COVID-19 pandemic, there is an urgent need for new antivirals and vaccines to combat its spread. The current study published on the preprint server bioRxiv in June 2020 shows some of the results of the extensive repurposing of already FDA-approved drugs.

23 Jun 2020

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Integrin-binding peptide ATN-161: Potential COVID-19 treatment

Now, a new study by researchers at Tulane University and published on the preprint server bioRxiv* in June 2020 reports the potential role of an integrin inhibitor ATN-161 to prevent ACE2-S protein binding.

17 Jun 2020

Researchers develop a simple tool for making mouse models of COVID-19

Until there are effective treatments or vaccines, the COVID-19 pandemic will remain a significant threat to public health and economies around the world. A major hurdle to developing and testing new anti-viral therapies and vaccines for COVID-19 is the lack of good, widely available animal models of the disease.

16 Jun 2020